Curcumin for Type 2 Diabetic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-31

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There are evidence that there is an association between insulin resistance and prolonged hyperinsulinemia or hyperglycemia in Type 2 diabetic patients. This will trigger oxidative stress system via reactive oxygen species (ROS) and lead to a high level of Nitric oxide. This can contribute to a significant change in blood vessel and could end up with the complications from cardiovascular disease and increased mortality rate of type 2 diabetic patients. The purpose of the present study was to examine the effectiveness of the curcumin in type 2 diabetic patients on the reduction of atherosclerosis events by examining pulse-wave velocity (PWV) and plasma high-sensitivity C-reactive protein (CRP) test and on blood sugar lowering, glycosylated hemoglobin (HBA1c), lipid profile, and insulin resistance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance

NCT01052025

Type 2 Diabetes Pre-diabetes Insulin Resistance +1 more

UNKNOWN PHASE4

Curcumin Supplementation and Patients With Type 2 Diabetes

NCT02529982

Non Insulin Dependent Diabetes

COMPLETED NA

Effects of Curcumin Supplementation on Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes

NCT02529969

Non Insulin Dependent Diabetes

UNKNOWN PHASE2/PHASE3

Curcumin's Effect on Diabetic Patients With Atherosclerotic Cardiovascular Risk

NCT05753436

Diabetes Mellitus, Type 2 Dyslipidemias Hypertension

COMPLETED PHASE2

Effects of Curcumin on Postprandial Blood Glucose, and Insulin in Healthy Subjects

NCT01029327

Diabetes

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus Cardiovascular Abnormalities

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Group Type PLACEBO_COMPARATOR

curcumin

Intervention Type DRUG

Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months

Curcumin

Group Type EXPERIMENTAL

curcumin

Intervention Type DRUG

Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

curcumin

Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Manufactured by Government Pharmaceutical Organization, Thailand

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with hyperlipidemia (Cholesterol ≥ 200 mg/dl, TG ≥ 150 mg/dl, LDL ≥ 100 mg/dl and HDL ≥ 35 mg/dl)
* Patient with hypertension (Blood pressure ≥ 130/85 mmHg or take hypertensive drugs)
* Obesity (BMI ≥ 25)

* Current diagnosis of cardiovascular disease, i.e., coronary arterial disease and cerebrovascular disease
* Current diagnosis of end stage renal function with serum creatinine \> 2.0 mg/dl or on renal dialysis
* Current diagnosis of cirrhosis with ALT ≥ 3 times of normal range

Minimum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No